AstraZeneca Partners with Immunocore

The day after announcing a partnership with UK’s Horizon Discovery, AstraZeneca have announced another oncology partnership with Immunocore, a UK biotechnology company. The agreement with Immunocore focuses around Immunocore’s ImmTAC technology.  The technology has created a platform of biological medicines which direct a patient’s T cells to specifically destroy only cancerous cells, avoiding damage to

Continue Reading

2014 Pharmaceutical Salary Survey Results

Would you like to know how your salary compares to other employees in similar physician jobs? The results of The Clinical Professionals Group’s 2014 European Pharmaceutical Salary Survey are now available.  If you would like a free salary survey results book, contact Daniel Patterson or Donna Wright on +44(0)118 952 2795. Earlier this year, The Clinical Professionals

Continue Reading

GSK Invests £25 Million into their Montrose, Scotland Facility

GSK Invests £25 Million into their Montrose, Scotland FacilityGlaxoSmithKline (GSK) have announced that they will invest £25 million to bring production of ingredients for four new pharmaceutical products to their site in Montrose, Scotland. The investment is expected to create 25 new jobs for process technicians, engineers and chemists, increasing the total GlaxoSmithKline workforce in

Continue Reading

Merck Revenues Fall in Quarter 3

Merck & Co have seen revenues drop by 4 per cent in their third quarter, as their diabetes blockbuster, Januvia, continued to show signs of weakness in the US. Sales were reported to be $11 billion, with Merck’s DPP-4 inhibitor Januvia (sitagliptin) down 5% to $927 million.  Line extension Janumet (sitagliptin and metformin) fared slightly

Continue Reading

Eli Lilly Announces Strong Q3 2013

Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payment of $787 million from

Continue Reading

Roche Announces Positive Q3 Results

Roche have revealed positive financial results for the third quarter, strengthened by the sustained growth of their cancer drugs. Earlier today Roche announced that sales reached 11.57 billion Swiss francs, an increase of 8%, while their pharmaceutical revenue grew by 9% to 9.03 billion Swiss francs. Roche’s best-selling drug was MabThera/Rituxan (rituximab), which has been

Continue Reading